The $35 million investment represents the second major investment in ProCure by McClendon Venture Company (MVC) and pushes the firm’s total investment in the growing proton therapy treatment company to $70 million. ProCure received an initial $35 million investment from MVC and several related individuals in December 2006.
ProCure will use the funds to support its ongoing development activities and corporate operations. ProCure’s Training and Development Center simulates all aspects of proton therapy treatment in a replica of a proton therapy treatment center without using actual protons. The Center provides clinical, technical, interpersonal and administrative training for the medical staff who will be involved with delivering the proton therapy treatment at ProCure’s facilities.